Big Numbers Ahead: Q2 Earnings, Fed Meeting, Jobs Week
https://www.zacks.com/stock/news/2311052/big-numbers-ahead-q2-earnings-fed-meeting-jobs-week?cid=CS-ZC-FT-ahead_of_wall_street-2311052
Jul 29, 2024 - Jobs Week, Fed Week and the busiest week of Q2 earnings so far await us.
0
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
https://www.zacks.com/stock/news/2310103/pharma-stock-roundup-azn-sny-abbv-q2-earnings-pfe-mrk-s-positive-pipeline-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2310103
Jul 26, 2024 - AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.
0
Billionaires Are Loading Up on This Surging Dow Stock. Should You?
https://www.fool.com/investing/2024/07/23/billionaires-are-loading-up-on-this-surging-dow-st/?source=iedfolrf0000001
Jul 23, 2024 - Merck stock has handily outperformed the Dow Jones Industrial Average in 2024, sparked by aggressive buying from billionaires like Citadel's Kenneth Griffin.
0
Elanco (ELAN) Stock Declines After Sale of Aqua Business
https://www.zacks.com/stock/news/2306111/elanco-elan-stock-declines-after-sale-of-aqua-business?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2306111
Jul 22, 2024 - Elanco (ELAN) completes the sale of Aqua Business to Merck Animal Health for $1.3 billion to strengthen its financial flexibility and accelerate debt reduction.
0
Top Research Reports for Exxon Mobil, Merck & Qualcomm
https://www.zacks.com/commentary/2300984/top-research-reports-for-exxon-mobil-merck-qualcomm?cid=CS-ZC-FT-research_daily-2300984
Jul 12, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Merck & Co., Inc. (MRK) and QUALCOMM Incorporated (QCOM), as well as two micro-cap stocks Armanino Foods of Distinction, Inc. (AMNF) and AMCON Distributing Company (DIT).
0
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
https://www.zacks.com/stock/news/2298543/eli-lilly-lly-to-buy-morphic-for-3-2b-boost-ibd-presence?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2298543
Jul 09, 2024 - Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.
0
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
https://www.zacks.com/stock/news/2297256/pharma-stock-roundup-fda-nod-to-lly-s-kisunla-sny-s-dupixent-gets-eu-nod-for-copd?cid=CS-ZC-FT-analyst_blog|stock_roundup-2297256
Jul 05, 2024 - Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
0
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
https://www.zacks.com/stock/news/2296924/roche-s-rhhby-combo-therapy-misses-lung-cancer-study-goals?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2296924
Jul 04, 2024 - Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.
0
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
https://www.zacks.com/stock/news/2296220/astrazeneca-azn-imfinzi-combo-gets-chmp-nod-for-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2296220
Jul 02, 2024 - The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.
0
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
https://www.zacks.com/stock/news/2295441/abbvie-abbv-gets-chmp-nod-for-lymphoma-drug-s-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2295441
Jul 01, 2024 - AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
0